Dr. Ehab Sorial, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 533
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
MA license 151686
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Southcoast Hospitals Group Fall River, MA
- Saint Anne's Hospital Fall River, MA
Medical groups
- Prima Care, PC (220 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 533
- Services billed
- 7,689
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 1,110 | 409 |
| Blood test, comprehensive group of blood chemicals | 822 | 412 |
| Blood test, lipids (cholesterol and triglycerides) | 741 | 404 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 610 | 384 |
| Blood test, thyroid stimulating hormone (tsh) | 512 | 375 |
| Established patient office or other outpatient visit, 20-29 minutes | 452 | 293 |
| Hemoglobin a1c level | 431 | 203 |
| Established patient office or other outpatient visit, 30-39 minutes | 387 | 238 |
| Advance care planning, first 30 minutes | 332 | 332 |
| Annual depression screening, 5 to 15 minutes | 331 | 331 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $21.06 in total to this clinician.
| Recor Medical Inc | $21.06 |
|---|
| Food and Beverage | $21.06 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 1 companies. The companies reported $309,206 in research payments for these studies, mostly to the institutions running them.
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company · Active, not recruiting · NCT06260722 - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Eli Lilly and Company · Active, not recruiting · NCT05433584 - Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Eli Lilly and Company · Completed · NCT06354660 - A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company · Recruiting · NCT06566170
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.